Medical/Pharmaceuticals

AskGene Limited Announces Completion of USD 20 Million Series A Financing Led by Qiming Venture Partners and TF Capital

CAMARILLO, Calif. and NANJING, China, May 8, 2022 /PRNewswire/ -- AskGene Limited ("AskGene"), a clinical-stage biopharmaceutical company focusing on discovery and development of innovative biological drugs, today announced the completion ofUSD 20 million in Series A financing. The financing was ...

2022-05-09 11:37 3129

SCG Cell Therapy announces clinical trial approval of TCR-T cell therapy for liver cancer in Singapore

*SCG101 - autologous T-cell receptor (TCR) T-cell therapy for liver cancer *SCG101 is the first TCR-T cell therapy product to receive a multi-country clinical trial approval from Singapore and China the treatment of HCC *APAC accounts for four in five new cases of liver across globally Singapor...

2022-05-09 10:28 3413

Takeda Malaysia receives coveted HR accolades by creating an exceptional people experience

Key points: * Takeda Malaysia receives Great Place to Work® award for the first time and Top Employer certification for the sixth consecutive year. * A significant majority of employees surveyed in Malaysia in 2021 Great Place to Work® Trust Index stated that Takeda is a great workplace. * ...

2022-05-09 09:05 2105

Takeda Singapore receives coveted HR accolades by creating an exceptional people experience

Key points: * Takeda Singapore receives Great Place to Work® award for the first time and Top Employer certification for the sixth consecutive year. * A significant majority of employees surveyed in Singapore in 2021 Great Place to Work® Trust Index stated that Takeda is a great workplace. ...

2022-05-09 09:00 1829

InxMed Raised $15 million in Series B+ Financing to Advance Innovative Therapies to Drug-resistant Cancers

NANJING, China, May 8, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicated to developing innovative therapies targeting stroma microenvironment and drug resistance for hard-to-treat solid tumors, today announced that it had completed $15 million in Series B+ Fin...

2022-05-09 08:04 1654

ExoCoBio Receives Japanese Patent for Alleviating Dermatitis with Adipose Stem Cell-Derived Exosome

* To lay a technological foundation for developing exosome-based medicines and cosmetic products for dermatitis treatment * To prove the technological feasibility of ExoSCRT™ for the mass-production of the world's best exosomes with high efficacy SEOUL, Korea, May 9, 2022 /PRNewswire/ -- ExoC...

2022-05-09 07:00 3058

Brii Bio Reports Progress on ESG Commitments in Its Inaugural ESG Report

DURHAM, N.C. and BEIJING, May 7, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company," stock code: 2137.HK), a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health...

2022-05-07 09:00 4860

Antengene to Participate in Three Upcoming Investor Conferences in May/June

CICC Healthcare Industry Forum 2022: May 9th to 12th BTIG Virtual China Biotech Day: June 1st Citi's 3rd Pan-Asia Regional Investor Conference 2022: June 8th to June 10th SHANGHAI and HONG KONG, May 6, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading inno...

2022-05-06 08:30 2481

Harbour BioMed Appoints Dr. Alexander A. Zukiwski to its Scientific Advisory Board

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, May 5, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX:02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, is pleased to announce the appointment o...

2022-05-06 08:00 1851

World Lupus Federation Global Survey of People Living with Lupus finds 87% Report at Least One Major Organ Affected by the Disease

Survey Findings Released in Advance of World Lupus Day on May 10 WASHINGTON, May 6, 2022 /PRNewswire/ -- In a recent international survey, the World Lupus Federation found that 87% of the survey respondents living with lupus reported that the disease has impacted one or more major organs or organ...

2022-05-06 07:00 2301

Insilico Medicine expands synthetic lethality portfolio with the nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers

NEW YORK, May 6, 2022 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company has nominated a preclinical candidate (PCC) targeting methionine adenosyltransferase 2A (MAT2A) from AI-de...

2022-05-06 05:00 2501

Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers

NEW YORK, May 5, 2022 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company has nominated a preclinical candidate (PCC) targeting methionine adenosyltransferase 2A (MAT2A) from AI-de...

2022-05-05 23:00 2548

AHRA and United Imaging launch a new program to develop exceptional leaders.

Announcing AHRA's Transformative Leaders of Choice Program HOUSTON, May 5, 2022 /PRNewswire/ -- AHRA, The Association for Medical Imaging Management, the professional organization representing all levels of management in hospital imaging departments, freestandin...

2022-05-05 22:15 1714

HOYA Vision Care Releases Results of First of its Kind Six-Year MiYOSMART Spectacle Lens Follow-up Clinical Study

Strong evidence shows continued long-term lens effectiveness in slowing myopia progression in children BANGKOK, May 5, 2022 /PRNewswire/ -- HOYA Vision Care, a leader in optical technology innovation, shared the results of asix-year follow-up clinical study on its award winning MiYOSMART spectac...

2022-05-05 22:12 2893

Daewoong Pharmaceutical announced first-quarter 2022 results

- Marked sales of KRW 272.2 billion and operating profit of KRW 26.8 billion - Reported record-high quarterly operating profit, thanks to highly profitable ETC drugs and export growth of Nabota - Expected to see increasing profitability and robust growth due to export expansion of Nabota and the...

2022-05-05 21:00 1724

TIKOMED and IQVIA announce a strategic collaboration for the development of TIKOMED's lead drug platform candidate ILB®

VIKEN, Sweden, May 5, 2022 /PRNewswire/ -- Today, Swedish biopharmaceutical company TikoMed AB and IQVIA announce a key strategic collaboration with the aim to accelerate the development of TikoMed's lead drug platform candidate ILB®, a broad-spectrum small molecule drug candidate with curative p...

2022-05-05 20:40 1420

SOPHiA GENETICS Announces Nomination of Jean-Michel Cosséry to Board of Directors

BOSTON and LAUSANNE, Switzerland, May 5, 2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a leader in data-driven medicine, today announced the nomination of Jean-Michel Cosséry to its Board of Directors. The Board of Directors will propose the appointment of Mr. Cosséry as a member of the Bo...

2022-05-05 20:27 1689

Leading HealthTech AI company NuraLogix announces new partnership with LaFiya TeleHealth

TORONTO, May 5, 2022 /PRNewswire/ -- NuraLogix, a leading HealthTech AI company, has announced a new partnership with LaFiya TeleHealth, a Nigerian-based telehealth platform which provides 24/7 virtual healthcare services to residents in remote and rural areas. LaFiya Telehealth provides medical...

2022-05-05 20:15 1718

I-Mab Provides Updates on Status under Holding Foreign Companies Accountable Act

SHANGHAI and GAITHERSBURG, Md., May 5, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today provided updates on its status under the Holding Foreign...

2022-05-05 20:00 1447

111, Inc. Provides Updates on its Status Under the Holding Foreign Companies Accountable Act

SHANGHAI, May 5, 2022 /PRNewswire/ -- 111 Inc. ( "111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company inChina, today announced that onMay 4th, 2022, the Securities and Exchange Commission (the "SEC") provisionally listed the Company as a "Commission-Identified ...

2022-05-05 17:18 1558
1 ... 248249250251252253254 ... 576